Welcome to the e-CCO Library!

P537: Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Subramaniam K.*1,2, Watthayalage R.1, Neeman T.3, Pavli P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P537: Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Roblin, X.(1)*;Williet, N.(2);Faure, J.(3);Bastide, L.(2);Barrau, M.(2);Paul, S.(4);
Created: Friday, 14 July 2023, 11:05 AM
P537: Steroid use in patients with immune checkpoint inhibitor colitis
Year: 2022
Source: ECCO'22
Authors: Crothers-Stomps, L.(1);Mohsen, W.(1);Kakkadasam Ramaswamy, P.(1);Mason, R.(2);Dzienis, M.(2);Edwards, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P537: The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Dulai*1, L. Peyrin-Biroulet2, K. Hahn3, N. Khalife4, D. Lindner5, K. Lasch6, D. Demuth7, H. Patel8, V. Jairath9

Created: Friday, 22 February 2019, 9:41 AM
P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Geldhof1, S. Volger2, C.B. Lin2, C. O’Brien2, I. Tikhonov2

Created: Thursday, 30 January 2020, 10:12 AM
P538: Can enteral polymeric diet change the post-surgical outcome in Crohn's disease patients? A pilot study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ceccarelli L.*1, Franceschi M.2, Bertani L.3, Nieri C.2, de Bortoli N.3, Mumolo G.1, Laino G.3, Albano E.3, Tapete G.3, Marchi S.3, Buccianti P.2, Costa F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P538: Enteral nutrition for the maintenance of remission in adults with inactive Crohn’s disease: A meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Tang*

Created: Thursday, 21 February 2019, 9:14 AM
P538: Implementation of Kono-S anastomosis as a new standard of surgical care
Year: 2022
Source: ECCO'22
Authors: Adamou, A.(1);Müller, G.(1);Iesalnieks, I.(1);
Created: Friday, 11 February 2022, 3:56 PM
P538: Suboptimal disease control is common in patients with Crohn's perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Gregorio, M.(1,2)*;D'Souza, B.(3,4);Connell, W.(1);Kamm, M.A.(1,2);Woods, R.(3);Connor, S.J.(5,6,7);Thompson, A.J.(1,2);Ding, N.S.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P538: The reliability of patient performed fecal calprotectin testing
Year: 2021
Source: ECCO'21 Virtual
Authors: Crouwel, F.(1);Dijkhuis, L.E.J.L.(1);Duijvestein, M.(1);Buiter, H.J.C.(2);De Boer, N.K.(1);Hamer, H.M.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Z. Shavit-Brunschwig1, O. Ledder1, G. Focht1, D. Urlep2, R. Lev-Tzion1, D. Marcus1, E. Broide3, A. Assa4, S. Hussey5, A. Yerushalmy-Feler6, A. Levine7, J. Markowitz8, C. Norden9, D. Turner*1

Created: Friday, 22 February 2019, 9:41 AM
P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. Lichtenstein1, B. Bressler2, S. Vermeire3, C. Francisconi4, N. Lawendy5, H. Shi5, L. Salese5, D. Judd5, E.V. Loftus Jr6

Created: Thursday, 30 January 2020, 10:12 AM
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.
Year: 2022
Source: ECCO'22
Authors: Shafrir, A.(1,2);Benson, A.A.(1);Zinger, A.(1);Shauli Aharonov, M.(3);Katz, L.H.(1);
Created: Friday, 11 February 2022, 3:56 PM
P539: Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004–2007 and 2010–2013
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Viola A.*1, Ferracane C.2, Costantino G.1, Alibrandi A.3, Inserra G.2, Fries W.1

Created: Wednesday, 20 February 2019, 10:36 AM
P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Del Arco1, P. Rivière1, F. Zerbib1, D. Laharie1, F. Poullenot1

Created: Friday, 22 February 2019, 9:41 AM
P539: Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schoefs, E.(1)*;Vermeire, S.(2);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Avedano, L.(3);De Rocchis, M.S.(3);Sajak-Szczerba, M.(3);Saldaña, R.(4);Straetemans, N.(5);Vandebroek, M.(6);Huys, I.(1);Janssens, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Konijeti1,2, B. Molparia2,3, E. Akhtar*, X. Wang2, J. Chang4, J. Lewis5, A. Chandrasekaran6, S. Groven7, G. Oliveira2, A. Torkamani2,3

Created: Thursday, 21 February 2019, 9:14 AM
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)
Year: 2021
Source: ECCO'21 Virtual
Authors: Afzali, A.(1);Kakehi, S.(2);Lapensee, K.(2);Lukanova, R.(3);Hennessy, F.(3);Knight, H.(3);Singh, K.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Levesque1, K. Taylor Meadows2, A. Buch3, M. Flynn4, K. Peters5, A. Olson1, J. Shen1, D. Slee6, C. Van Biene7, R. Aranda1, N. Vande Casteele8, G. Opiteck1

Created: Thursday, 30 January 2020, 10:12 AM
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Mezzina1*, A. Cassinotti1, S. Carmagnola1, A. Massari1, S. Grillo2, S. Landi2, G. Maconi1, S. Ardizzone1

Created: Thursday, 21 February 2019, 9:14 AM